Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?
- PMID: 11698269
- DOI: 10.1182/blood.v98.10.2900
Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?
Abstract
Hematopoietic stem cells from 4 different sources have been or are being used for the reconstitution of lymphohematopoietic function after myeloablative, near-myeloablative, or nonmyeloablative treatment. Bone marrow (BM)-derived stem cells, introduced by E. D. Thomas in 1963, are considered the classical stem cell source. Fetal liver stem cell transplantation has been performed on a limited number of patients with aplastic anemia or acute leukemia, but only transient engraftment has been demonstrated. Peripheral blood as a stem cell source was introduced in 1981, and cord blood was introduced as a source in 1988. The various stem cell sources differ in their reconstitutive and immunogenic characteristics, which are based on the proportion of early pluripotent and self-renewing stem cells to lineage-committed late progenitor cells and on the number and characteristics of accompanying "accessory cells" contained in stem cell allografts.
Similar articles
-
Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.Transpl Immunol. 1996 Dec;4(4):319-23. doi: 10.1016/s0966-3274(96)80054-2. Transpl Immunol. 1996. PMID: 8972563
-
Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum.Blood. 1994 Dec 1;84(11):3948-55. Blood. 1994. PMID: 7524753 Clinical Trial.
-
Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.Blood. 1996 Jul 1;88(1):353-7. Blood. 1996. PMID: 8704195 Clinical Trial.
-
Allogeneic peripheral blood progenitor cells: current status and future directions.J Hematother. 1996 Aug;5(4):331-7. doi: 10.1089/scd.1.1996.5.331. J Hematother. 1996. PMID: 8877708 Review.
-
[Allogeneic hematopoietic stem cell transplantations].Transfus Clin Biol. 2011 Apr;18(2):235-45. doi: 10.1016/j.tracli.2011.02.021. Epub 2011 Apr 3. Transfus Clin Biol. 2011. PMID: 21466967 Review. French.
Cited by
-
Peripheral blood versus bone marrow transplant in patients with aplastic anemia, an unresolved issue.Bone Marrow Transplant. 2016 Dec;51(12):1628-1630. doi: 10.1038/bmt.2016.235. Epub 2016 Sep 26. Bone Marrow Transplant. 2016. PMID: 27668763 No abstract available.
-
Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.Front Immunol. 2020 Feb 14;11:191. doi: 10.3389/fimmu.2020.00191. eCollection 2020. Front Immunol. 2020. PMID: 32117310 Free PMC article. Review.
-
Establishment of reference values based on influential characteristics of hematopoietic stem cells and immune cell subsets in the bone marrow.Heliyon. 2024 May 8;10(9):e30888. doi: 10.1016/j.heliyon.2024.e30888. eCollection 2024 May 15. Heliyon. 2024. PMID: 38774070 Free PMC article.
-
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.Biol Blood Marrow Transplant. 2018 Feb;24(2):343-352. doi: 10.1016/j.bbmt.2017.10.023. Epub 2017 Oct 18. Biol Blood Marrow Transplant. 2018. PMID: 29055682 Free PMC article.
-
Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model.Cell Host Microbe. 2010 Sep 16;8(3):284-91. doi: 10.1016/j.chom.2010.08.001. Cell Host Microbe. 2010. PMID: 20833379 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
